Prostate Support
Prostate Support, licence 80065059: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Blume Wellness Inc.
- NPN or DIN-HM
- 80065059
- Status
- Active licence
- Licence date
- 6 November 2015
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Urtica dioica L.: L'étiquetage des compléments alimentaires contenant les parties souterraines de cette plante doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Fruit Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 640 mg | 160.0 mg | Not calculated |
| Cucurbita pepo Source : New material Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 400 mg | 100.0 mg | Not calculated |
| Solanum lycopersicum Source : Chair (fruit) Potency : 5.0 % Lycopene | 100.0 mg | Not calculated |
| Urtica dioica Source : Racine | 75.0 mg | Not calculated |
| Prunus africana Source : Écorce âgée | 60.0 mg | Not calculated |
Non-medicinal ingredients
Cellulose, Gélatine, Stéarate de magnésium, Silice
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | minimum: 2.0 Capsule ; maximum: 3.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia. Helps to support prostate health. Provides antioxidants for the maintenance of good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer. Consult a healthcare practitioner if symptoms persist or worsen.
- Effets indésirables connus
Discontinue treatment if symptoms of diarrhea, constipation, dizziness, gastric pain, and visual disturbances appear; consult a healthcare practitioner.
Source
Official Health Canada record, licence 80065059
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.